Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520027 | 1.00 | REN (0.41) | RENCYP3A4KCNH2SLC6A2SLC6A4 | |
| SCHEMBL4529032 | 0.80 | REN (0.42) | RENCYP3A4KCNH2 | |
| SCHEMBL4528587 | 0.76 | REN (0.42) | RENCYP3A4 | |
| SCHEMBL4537821 | 0.72 | REN (0.42) | RENCYP3A4 | |
| SCHEMBL4523064 | 0.70 | REN (0.36) | RENCYP3A4KCNH2SLC6A2SLC6A4 | |
| SCHEMBL4523060 | 0.70 | REN (0.36) | RENCYP3A4KCNH2SLC6A2SLC6A4 | |
| SCHEMBL661968 | 0.68 | REN (0.60) | RENCYP3A4 | |
| SCHEMBL661967 | 0.68 | REN (0.60) | RENCYP3A4 | |
| SCHEMBL5942264 | 0.64 | REN (0.47) | RENCYP3A4 | |
| SCHEMBL4538013 | 0.64 | DUT (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | REN 1/4885CYP3A4 534/4885KCNH2 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.